Get our introductory offer at only
*$0.99/month for first 3 months
$29.90/month for the next 9 months
NOVARTIS is taking aim at drug-resistant malaria - a growing global problem - by launching clinical trials of the first new antimalarial medicine for many years in nine countries across Africa and Asia.
The Swiss drugmaker, which is working on the mid-stage Phase IIb trial